3 Dull Stocks With Exciting Potential
Though they may not be the most exciting businesses around, an investment in these 3 dull stocks can bring big rewards to the patient investor.
June 28, 2019

Some things in life, like waffles and roller-coasters, should never be boring. Others, such as a transatlantic plane journey or a visit to the dentist, are probably better off without too much excitement.

We can add certain stocks to that list, too.

In his classic book, 'One Up On Wall Street', investor Peter Lynch wrote that he actively seeks out boring stocks with dull names as part of his investing strategy:

"A company that does boring things is almost as good as a company that has a boring name, and both together is terrific."

Here are three companies that best demonstrate how boring can often be best.

1. DocuSign

DocuSign (NASDAQ: DOCU) is a SaaS company that provides electronic signature technology for facilitating exchanges of documents. Sounds thrilling, right?

Although it's unlikely to gain a cult following any time soon, the company, which went public in April of last year, has managed to become a permanent fixture in the operations of countless businesses. Indeed, DocuSign's technology is already used by 18 of the top 20 global pharmaceutical companies and 7 of the top 10 technology companies.

With more than 500,000 paying customers and hundreds of millions of users under its belt, DocuSign has turned something as mundane as the process of signing a contract into a high-growth business that makes up in growth-potential what it lacks in glamour.

2. Markel Corp.

Like DocuSign, Markel (NYSE: MKL) will never win a prize in the excitement department, but it offers something that faddish start-ups rarely can: a history of incredible returns.

Markel, in its own words, is a -- wait for it -- "holding company for insurance, reinsurance, and investment operations around the world." It has performed so well in this space that it has acquired the nick-name 'Baby Berkshire'.

If insurance doesn't rock the boat for you, then how about this? Markel's stellar reputation comes from its track-record of consistently beating the S&P 500, particularly in recent years. Indeed, if you'd bought $1,000 in Markel stock when the company was founded in 1986, your investment would be worth more than $100,000 today.

3. Veeva Systems

Founded in 2007, Veeva Systems (NYSE: VEEV) provides cloud-based software that makes life-science companies more efficient.

Read that sentence again. "Cloud-based software." "Life-science." "Efficient." That's right, Veeva is out there at the cutting-edge of monotony.

Sometimes described as the Salesforce(NYSE: CRM) of pharma, Veeva was actually co-founded by Peter Gassner, who built Salesforce's customer relationship management (CRM) platform, which is now the largest enterprise cloud-computing platform in the world.

Veeva has achieved a similar level of dominance in its own space, with the company's CRM being used by about 80% of the global pharma and life sciences industry.

As growth inevitably slows down in its core business, Veeva is investing in its highly-successful Vault content management products, which are expected to see growth of 40% by the end of the fiscal year. With shares recently reaching all-time highs, it looks like the future may indeed be exciting for Veeva.

Read More From MyWallSt:

MyWallSt operates a full disclosure policy. MyWallSt staff currently hold long positions in DocuSign and Veeva Systems . Read our full disclosure policy here.

The Home of Successful Investing.

© 2023 MyWallSt Ltd. All rights reserved.







This website is operated by MyWallSt Ltd (“MyWallSt”). MyWallSt is a publisher and a technology platform, not a registered broker-dealer or registered investment adviser, and does not provide investment advice. All information provided by MyWallSt Limited is of a general nature for information and education purposes, and you should not construe any such information as investment advice. MyWallSt Limited does not take your specific needs, investment objectives or financial situation into consideration, and any investments mentioned may not be suitable for you. You should always carry out your own independent verification of facts and data before making any investment decisions, as we cannot guarantee the accuracy or completeness of any information we publish and any opinions that we publish may be wrong and may change at any time without notice. If you are unsure of any investment decision you should seek a professional financial advisor. MyWallSt Limited is not a registered investment adviser and we do not provide regulated investment advice or recommendations. MyWallSt Limited is not regulated by the Central Bank of Ireland. MyWallSt Limited may provide hyperlinks to web sites operated by third parties. Your use of third party web sites and content, including without limitation, your use of any information, data, advertising, products, or other materials on or available through such web sites, is at your own risk and is subject to the third parties' terms of use.